Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30744447 | 1.00 | MEN1 (0.63) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL8541822 | 0.83 | KDM4E (0.58) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL20771833 | 0.83 | MAOB (0.51) | MEN1KMT2AKDM4EALDH1A1MAOB | |
| SCHEMBL6162263 | 0.83 | RAB9A (0.48) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL9045204 | 0.83 | MAOB (0.53) | MEN1KMT2AKDM4EL3MBTL1MAOB | |
| SCHEMBL24570677 | 0.83 | MEN1 (0.58) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL12967186 | 0.83 | MEN1 (0.58) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL6160873 | 0.83 | LOXL2 (0.58) | ALDH1A1MAOBLOXL2HTTMMP13 | |
| SCHEMBL27299802 | 0.83 | MAP4K4 (0.46) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL27299560 | 0.81 | MAOB (0.50) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4565575-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Alivexis, Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220363685-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-11-17 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011078370-A1 | NOVEL PARABANIC ACID DERIVATIVE AND DRUG HAVING THE SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | MEN1 154/4885KMT2A 909/4885KDM4E 730/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | MEN1 3549/4885KMT2A 634/4885KDM4E 1156/4885 |
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TST, QSOX1, MMP1 | MEN1 4321/4885KMT2A 2631/4885KDM4E 2471/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | MEN1 154/4885KMT2A 909/4885KDM4E 730/4885 |
| US-20220363685-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | MEN1 154/4885KMT2A 909/4885KDM4E 730/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | MEN1 154/4885KMT2A 909/4885KDM4E 730/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | MEN1 154/4885KMT2A 909/4885KDM4E 730/4885 |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KIT, LTK, HRH3 | MEN1 2777/4885KMT2A 1117/4885KDM4E 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.